|  | Race | |
---|---|---|---|
Total | African-American | White | |
(N = 342) | (N = 174) | (N = 168) | |
Demographic characteristics | |||
Age at diagnosis (years) | |||
  Mean (SD) | 55.25 (13.20) | 55.71 (13.91) | 54.78 (12.43) |
BMI (kg/m2),n(%) | |||
  < 25 | 126 (37.1) | 40 (23.3) | 86 (51.2) |
  25 to < 30 | 85 (25.0) | 43 (25.0) | 42 (25.0) |
  ≥ 30 | 129 (37.9) | 89 (51.7) | 40 (23.8) |
Smoking status,n(%) | |||
  Non-smoker | 225 (67.0) | 111 (64.5) | 114 (69.5) |
  Past smoker | 87 (25.9) | 44 (25.6) | 43 (26.2) |
  Current smoker | 24 (7.1) | 17 (9.9) | 7 (4.3) |
Age at menarche (years) | |||
  Mean (SD) | 12.68 (1.66) | 12.59 (1.69) | 12.77 (1.63) |
Parity | |||
  Nulliparous | 44 (15.0) | 19 (13.1) | 25 (16.9) |
  Parous (1+ live births) | 249 (85.0) | 126 (86.9) | 123 (83.1) |
History of breastfeedinga,n(%) | |||
  No | 75 (39.5) | 38 (45.2) | 37 (34.9) |
  Yes | 115 (60.5) | 46 (54.8) | 69 (65.1) |
Menopausal status,n(%) | |||
  Pre-/perimenopausal | 117 (36.1) | 59 (36.9) | 58 (35.4) |
  Postmenopausal | 207 (63.9) | 101 (63.1) | 106 (64.6) |
Age at menopauseb,n(%) | |||
  < 45 years | 83 (45.4) | 46 (53.5) | 37 (38.1) |
  45 to < 50 years | 35 (19.1) | 17 (19.8) | 18 (18.6) |
  50 to < 55 years | 50 (27.3) | 17 (19.8) | 33 (34.0) |
  ≥ 55 years | 15 (8.2) | 6 (7.0) | 9 (9.3) |
History of hormone replacement therapy useb,n(%) | |||
  No | 120 (63.8) | 66 (75.0) | 54 (54.0) |
  Yes | 68 (36.2) | 22 (25.0) | 46 (46.0) |
Family history of breast cancer among first-degree relatives,n(%) | |||
  No | 240 (73.6) | 118 (74.2) | 122 (73.1) |
  Yes | 86 (26.4) | 41 (25.8) | 45 (26.9) |
Diabetes status,n(%) | |||
  No | 298 (87.1) | 140 (80.5) | 158 (94.0) |
  Yes | 44 (12.9) | 34 (19.5) | 10 (6.0) |
Hypertension status,n(%) | |||
  No | 200 (58.5) | 82 (47.1) | 118 (70.2) |
  Yes | 142 (41.5) | 92 (52.9) | 50 (29.8) |
High cholesterol status,n(%) | |||
  No | 286 (83.6) | 141 (81.0) | 145 (86.3) |
  Yes | 56 (16.4) | 33 (19.0) | 23 (13.7) |
Clinical characteristics | |||
ER status,n(%) | |||
  Positive | 267 (79.0) | 120 (70.2) | 147 (88.0) |
  Negative | 71 (21.0) | 51 (29.8) | 20 (12.0) |
Stage,n(%) | |||
  Stage I | 163 (47.7) | 76 (43.7) | 87 (51.8) |
  Stage II | 135 (39.5) | 75 (43.1) | 60 (35.7) |
  Stage III | 44 (12.9) | 23 (13.2) | 21 (12.5) |
Tumor grade,n(%) | |||
  Well differentiated | 75 (22.9) | 30 (18.2) | 45 (27.6) |
  Moderately differentiated | 150 (45.7) | 68 (41.2) | 82 (50.3) |
  Poorly differentiated | 103 (31.4) | 67 (40.6) | 36 (22.1) |
Tumor size (cm),n(%) | |||
  ≤ 0.5 | 7 (2.4) | 2 (1.4) | 5 (3.3) |
  0.5 to < 1 | 43 (14.5) | 20 (13.9) | 23 (15.0) |
  1 to < 5 | 222 (74.7) | 102 (70.8) | 120 (78.4) |
  ≥ 5 | 25 (8.4) | 20 (13.9) | 5 (3.3) |
Number of positive lymph nodes,n(%) | |||
  0 | 204 (65.6) | 101 (64.7) | 103 (66.5) |
   ≥ 1 | 107 (34.4) | 55 (35.3) | 52 (33.5) |
Chemotherapy,n(%) | |||
  No | 172 (52.4) | 70 (43.5) | 102 (61.1) |
  Yes | 156 (47.6) | 91 (56.5) | 65 (38.9) |
Radiation,n(%) | |||
  No | 235 (71.4) | 105 (65.2) | 130 (77.4) |
  Yes | 94 (28.6) | 56 (34.8) | 38 (22.6) |
Hormone therapy,n(%) | |||
  No | 109 (31.9) | 71 (40.8) | 38 (22.6) |
  Yes | 233 (68.1) | 103 (59.2) | 130 (77.4) |